Literature DB >> 1981715

Pharmacokinetics of the anti-AIDS drug 2',3'-dideoxyinosine in the rat.

G F Ray1, W D Mason, M Z Badr.   

Abstract

The pharmacokinetics of 2',3'-dideoxyinosine (ddlno) was examined in the male Fischer 344 rat using reversed phase HPLC with UV and radiochemical detection. Following iv doses of 12, 25, and 100 mg/kg, the parent drug was rapidly eliminated from plasma (mean residence time, 6.3 min; systemic clearance, 64 ml/min/kg). The mean terminal elimination half-life was 28 min and the volume of distribution at steady state was 0.39 liter/kg. Orally administered [3H]ddlno (100 mg/kg) was not significantly bioavailable in the rat, with only 8-11% of the dose absorbed as the parent compound over a 2 hr period. Peak plasma drug concentrations occurred 10 to 20 min following oral administration. Solution stability data suggested that ddlno was unstable at gastric pH (pH 1, t1/2 less than 30 sec). However, elevation of gastric pH with sodium bicarbonate prior to oral administration of ddlno was not effective in increasing the bioavailability of the parent drug. The drug and its metabolic products were extensively distributed into rat tissue 48 hr after iv or oral administration. Following iv infusion of [3H]ddlno to steady state conditions, the highest tissue-to-plasma ratios of radioactivity were found in the kidney (2.2), liver (1.7), and spleen (1.5). Renal clearance accounted for 99% of the eliminated dose. Liver perfusion studies showed that ddlno was not subject to significant hepatic clearance (less than 10%) and that the metabolism was not inducible with phenobarbital.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1981715

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  9 in total

1.  Effects of 2',3'-dideoxyinosine on Toxoplasma gondii cysts in mice.

Authors:  M E Sarciron; P Lawton; C Saccharin; A F Petavy; F Peyron
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

2.  Comparative pharmacokinetics, distributions in tissue, and interactions with blood proteins of conventional and sterically stabilized liposomes containing 2',3'-dideoxyinosine.

Authors:  P Harvie; A Désormeaux; M C Bergeron; M Tremblay; D Beauchamp; L Poulin; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

3.  Physiologically based pharmacokinetic models of 2',3'-dideoxyinosine.

Authors:  H J Kang; M G Wientjes; J L Au
Journal:  Pharm Res       Date:  1997-03       Impact factor: 4.200

4.  Absorption of 2',3'-dideoxyinosine from lower gastrointestinal tract in rats and kinetic evidence of different absorption rates in colon and rectum.

Authors:  S L Bramer; M G Wientjes; J L Au
Journal:  Pharm Res       Date:  1993-05       Impact factor: 4.200

Review 5.  Didanosine. A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection.

Authors:  D Faulds; R N Brogden
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

6.  Percutaneous absorption of 2',3'-dideoxyinosine in rats.

Authors:  E Mukherji; N J Millenbaugh; J L Au
Journal:  Pharm Res       Date:  1994-06       Impact factor: 4.200

7.  Pharmacokinetics of 2',3'-dideoxyinosine in monkeys.

Authors:  M X Qian; T S Finco; A R Swagler; J M Gallo
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

8.  Enhanced oral bioavailability of DDI after administration of 6-Cl-ddP, an adenosine deaminase-activated prodrug, to chronically catheterized rats.

Authors:  B D Anderson; M E Morgan; D Singhal
Journal:  Pharm Res       Date:  1995-08       Impact factor: 4.200

9.  Pharmacokinetic properties of a novel inosine analog, 4'-cyano-2'-deoxyinosine, after oral administration in rats.

Authors:  Mai Hashimoto; Kazuaki Taguchi; Takako Ishiguro; Satoru Kohgo; Shuhei Imoto; Keishi Yamasaki; Hiroaki Mitsuya; Masaki Otagiri
Journal:  PLoS One       Date:  2018-06-06       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.